Inventor
Weiqiang XING
Inventor
CN
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
C07DHeterocyclic compounds26%
A61KPreparations for medical, dental or toiletry purposes23%
C07BGeneral methods of organic chemistry13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
Y02PClimate change mitigation technologies in the production or processing of goods6%
PatentTitleYear
12,595,264Heterocyclic GLP-1 agonists202612,441,706Protein degradation agent compound preparation method and application202512,234,223Phthalazinone compound, and preparation method therefor and medical use thereof202512,221,442Heterocyclic GLP-1 agonists202512,195,457Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative202511,926,626Heterocyclic GLP-1 agonists202411,926,643Heterocyclic GLP-1 agonists202411,767,312Phthalazinone compound, and preparation method therefor and medical use thereof2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2025Patents assigned to JIANGXI JEMINCARE GROUP CO LTD (4)· patent assignee history
2023–2025Patents assigned to SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (4)· patent assignee history
2023Patents assigned to GENENTECH INC (1)· patent assignee history
2023–2026Based in CN· patent location history
2024–2026Patents assigned to GASHERBRUM BIO INC (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GASHERBRUM BIO INC | 4 | 2024–2026 |
| JIANGXI JEMINCARE GROUP CO LTD | 4 | 2023–2025 |
| SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD | 4 | 2023–2025 |
| GENENTECH INC | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 8 | 2023–2026 |